NASDAQ$ESTA

Establishment Labs Holdings Inc · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

Reported record second quarter financial results and raised full year guidance.

Establishment Labs reported a record second quarter revenue of $32.0 million, a 205% increase year-over-year. The company raised its full year 2021 revenue guidance to a new range of $122 million to $126 million.

  • Second quarter worldwide sales reached $32.0 million, a 205% increase year-over-year.
  • 2021 guidance increased to a new range of $122 million to $126 million, representing a 44% to 49% increase over 2020.
  • Second quarter operating expenses were $26.1 million, a 55% increase compared to the second quarter of 2020.
  • Total net cash burn was $1.1 million in the second quarter, with a cash balance of $76.8 million as of June 30, 2021.

Headline financials

Total Revenue

$32M

Previous: $10.5M+205.5%
EPS (adj)

-$0.22

Previous: -$0.45+51.1%
Capital Expenditures

-$1.7M

Previous: -$1.29M-32.1%
Free Cash Flow

-$7.03M

Previous: -$11.8M+40.3%
Net Income

-$5.32M

Previous: -$10.5M+49.2%
Operating Income

-$4.63M

Previous: -$9.6M+51.7%
Gross Profit

$21.5M

Previous: $7.23M+196.8%
Cash & Equivalents

$76.8M

Previous: $86.4M-11.1%
Total Assets

$152M

Previous: $157M-3.0%
Stock-Based Comp

$2.56M

Previous: $1.56M+64.2%

Revenue & EPS history

Establishment Labs · Revenue · Quarterly

$32M

Q2 2021+205.5%vs Q2 2020
Beat estimate in 10 of 16 quarters(63%)
ActualEstimate

Forward guidance

The company raised its full year 2021 revenue guidance to a new range of $122 million to $126 million.

Tailwinds

  • Strong second quarter revenue growth of 205% year-over-year.
  • Increased full year 2021 revenue guidance.
  • Publication of landmark study showing superior biocompatibility of Motiva® SmoothSilk® implant technology.
  • Expanding marketing and commercial activities with Motiva Ergonomix2®.
  • Continuing commercial launch of Motiva Flora® tissue expander in Europe.

Headwinds

  • Ongoing challenges from the pandemic.
  • Net loss from operations for the second quarter was $5.3 million.
  • Cash decreased $7.7 million from December 31, 2020.
  • Total operating expenses for the second quarter were $26.1 million.
  • R&D expenses increased approximately $2.0 million to $4.3 million

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

+1.5%

Avg return

Earnings day

+0.7%

Avg return

5 days after

+2.4%

Avg return

30 days after

56%

18 / 32 earnings

Positive

+22.5%

Q3 2025

Best reaction

-26.0%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.4%-4.3%+2.9%
Q4 2025-1.9%+5.0%-20.1%
Q3 2025+22.5%+37.0%+43.2%
Q1 2025+4.9%+5.1%+14.2%
Q4 2024+17.9%+28.1%+12.1%
Q3 2024-5.2%-13.2%-10.0%
Q2 2024+3.4%+20.6%+23.5%
Q1 2024+5.4%+4.2%-10.8%
Q4 2023+15.1%+19.6%+28.2%
Q3 2023-26.0%-36.1%-31.7%
Q2 2023-8.4%-12.0%-12.2%
Q1 2023+1.8%-1.6%-1.9%
Q4 2022+7.2%+10.3%+0.3%
Q3 2022-7.7%+11.1%+27.1%
Q2 2022-3.0%+1.3%-0.4%
Q1 2022-10.5%-10.1%+2.3%
Q4 2021+3.3%+1.6%+11.5%
Q3 2021-10.6%-14.3%-15.2%
Q2 2021+6.0%-3.7%-3.1%
Q1 2021-0.6%-1.8%+8.9%
Q4 2020+0.4%-6.8%+9.5%
Q3 2020+8.9%-0.4%+22.6%
Q2 2020+6.2%+7.3%+9.3%
Q1 2020+2.9%+0.5%+15.3%
Q4 2019+4.5%-16.4%+0.4%
Q3 2019-0.3%+0.5%+7.8%
Q2 2019-5.2%-10.6%-10.2%
Q1 2019+1.5%-0.3%-15.9%
Q4 2018-1.9%-4.9%-15.2%
Q3 2017+10.3%+4.5%-6.2%
Q3 2018+10.3%+4.5%-6.2%
Q2 2018-2.7%-2.9%-3.4%
Q4 2017
Q2 2017
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro